| 000 | 02839cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032449.0 | ||
| 008 | 191127s2019 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.33.M.Sc.2019.Ah.R | ||
| 100 | 0 | _aAhmed Bahaa Eldin Abbas | |
| 245 | 1 | 2 |
_aA randomized study comparing moxifloxacin, omeprazole, nitazoxanide, and doxycycline versus classic triple therapy for the eradication of helicobacter pylori / _cAhmed Bahaa Eldin Abbas ; Supervised Maissa Elsaid Elraziky , Mohammad Elsayed Soliman , Walied Khalid Alhossary |
| 246 | 1 | 5 | _aدراسة عشوائية تقارن بين الموكسيفلوكساسين والاوميبرازول والنيتازوكسانيد و الدوكسيسيكلين مقابل العلاج الثلاىى الكلاسيكى في علاج البكتيريا الحلزونيه |
| 260 |
_aCairo : _bAhmed Bahaa Eldin Abbas , _c2019 |
||
| 300 |
_a75 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine | ||
| 520 | _aIntroduction:Helicobacter pylori infection is a global concern with rising antimicrobial resistance and declining cure rates which has led to an increased demand for a more efficacious, yet tolerable, therapy. Aim: To evaluate the efficacy and safety of the two regimens (Amoxicillin, clarithromycin and omeprazole for 14 days vs moxifloxacin, doxycycline, nitazoxanide and omeprazole for 14 days) as a first-line treatment for Helicobacter pylori (H. pylori) infection. Patients &Methods: From September 2018 to April 2019, 90 patients with confirmed H. pylori infection were randomized into two groups.The First group (triple group)(n = 44) received amoxicillin 1000 mg, clarithromycin500 mg and Omeprazole 40 mg twice a day for 14 days, the Second group (MOND group) (n = 46) received Moxifloxacin 400 mg, Doxycycline 100 mg once daily, Nitazoxanide 500 mg and Omeprazole 40 mg twice a day for 14 days. Successful eradication of H. pylori infection was defined as a negative Stool antigen test 6 weeks after the end of treatment. Patient compliance was defined as 2good3 if drug intake was at least 90%.Follow up of patient'sadherenceto treatment, adverse event rates and dyspepsia improvement was done 6 weeks after theend of treatment | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aHelicobacter pylori | |
| 653 | 4 | _aMoxifloxacin | |
| 653 | 4 | _aTreatment | |
| 700 | 0 |
_aMaissa Elsaid Elraziky , _eSupervisor |
|
| 700 | 0 |
_aMohammad Elsayed Soliman , _eSupervisor |
|
| 700 | 0 |
_aWalied Khalid Alhossary , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c75503 _d75503 |
||